Korean J Physiol Pharmacol.  2023 Sep;27(5):493-511. 10.4196/kjpp.2023.27.5.493.

Inhibition of the interaction between Hippo/YAP and Akt signaling with ursolic acid and 3′3-diindolylmethane suppresses esophageal cancer tumorigenesis

• Meng RY
• Li CS
• Hu D
• Kwon SG
• Jin H
• Chai OH
• Lee JS
• Kim SM

• KMID: 2545539
• DOI: http://doi.org/10.4196/kjpp.2023.27.5.493

Abstract

Hippo/YAP signaling hinders cancer progression. Inactivation of this pathway contributes to the development of esophageal cancer by activation of Akt. However, the possible interaction between Akt and Hippo/YAP pathways in esophageal cancer progression is unclear. In this study, we found that ursolic acid (UA) plus 3′3-diindolylmethane (DIM) efficiently suppressed the oncogenic Akt/Gsk-3β signaling pathway while activating the Hippo tumor suppressor pathway in esophageal cancer cells. Moreover, the addition of the Akt inhibitor LY294002 and the PI3K inhibitor 3-methyladenine enhanced the inhibitory effects of UA plus DIM on Akt pathway activation and further stimulated the Hippo pathway, including the suppression of YAP nuclear translocation in esophageal cancer cells. Silencing YAP under UA plus DIM conditions significantly increased the activation of the tumor suppressor PTEN in esophageal cancer cells, while decreasing p-Akt activation, indicating that the Akt signaling pathway could be down-regulated in esophageal cancer cells by targeting PTEN. Furthermore, in a xenograft nude mice model, UA plus DIM treatment effectively diminished esophageal tumors by inactivating the Akt pathway and stimulating the Hippo signaling pathway. Thus, our study highlights a feedback loop between the PI3K/Akt and Hippo signaling pathways in esophageal cancer cells, implying that a low dose of UA plus DIM could serve as a promising chemotherapeutic combination strategy in the treatment of esophageal cancer.

Keyword

3′,3-diindolylmethane; Akt; Esophageal squamous cancer cells; Hippo signaling pathway; Ursolic acid; YAP

Figure

• 

  Fig. 1 Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) inhibits cell growth and promotes apoptosis in ESCC. (A) UA and DIM combination therapy inhibited cell viability in TE-8 and TE-12 cells. Cells were treated with UA (20 μM), DIM (50 μM), and combination treatment for 48 h. An EZ-CYTOX assay kit was used to assess the cell viability of esophageal cancer cells and to generate growth curves. (B) UA plus DIM combination reduced colony number and size in TE-8 and TE-12 cells. Colonies were cultured with UA (20 μM), DIM (50 μM), and the combination treatment of UA and DIM for 4 weeks in soft agar gel. The quantification of colony numbers was calculated by ImageJ. (C) UA plus DIM increased early-stage and late-stage apoptosis in TE-8 and TE-12 cells. Annexin V/PI staining was performed to detect cell apoptosis by flow cytometry. (D) UA plus DIM combination induced subG1 phase cell accumulation in TE-8 and TE-12 cells. Cells were treated with UA (20 μM), DIM (50 μM), and combination treatment for 48 h. SubG1 phase cells were indicated by apoptosis markers and detected by flow cytometry. (E) UA plus DIM enhanced apoptosis-related protein levels. Expression of apoptosis-regulatory factor proteins caspase-9/cleaved-caspase-9 and PRAP/cleaved-PARP were examined by Western blot analysis. The quantification of protein bands was estimated by ImageJ software. GAPDH was used as the internal control. Data are expressed as the mean ± standard error of the mean. CONT, control; DMSO, dimethyl sulfoxide; ESCC, esophageal squamous cell carcinoma; PI, propidium iodide; n.s., no significant. *, compared to the control; #, compare with UA plus DIM combination treatment. * or #, p < 0.05; ** or ##, p < 0.01.

• 

  Fig. 2 Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) induces G1 phase arrest in ESCC. (A) UA plus DIM induced G1 phase arrest in TE-8 and TE-12 cells. Cells were treated with UA (20 μM), DIM (50 μM), and a combination of both for 48 h. PI staining-based flow cytometry assay was designed to study the cell cycle in esophageal cancer cells. (B) UA plus DIM combination suppressed G1 phase-related protein levels. Western blot analysis was performed to measure G1 phase-related protein CDK4, CDK6, and cyclin D1. GAPDH was used as the internal control. Data are expressed as the mean ± standard error of the mean. CONT, control; ESCC, esophageal squamous cell carcinoma; PI, propidium iodide; n.s., no significant. *, compared to the control; #, compare with UA plus DIM combination treatment. * or #, p < 0.05; ** or ##, p < 0.01.

• 

  Fig. 3 Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) suppresses cell migration in ESCC. (A) UA (20 μM) and DIM (50 μM) combination treatment inhibited cell migration in the presence of 5 µg/ml mitomycin-C. Wound healing assays were used to analyze cell migration. TE-8 and TE-12 cell migration rates were measured at 12 h and 24 h after UA or DIM single treatment or a combination and calculated by ImageJ software. (B) UA plus DIM inhibited migration-related protein expression. Migration-related proteins E-cadherin, MMP-13, and MMP-9 were examined by Western blot analysis. GAPDH was used as the internal control. Data are expressed as the mean ± standard error of the mean. CONT, control; ESCC, esophageal squamous cell carcinoma; n.s., no significant. *, compared to the control; #, compare with UA plus DIM combination treatment. * or #, p < 0.05; ** or ##, p < 0.01.

• 

  Fig. 4 Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) inactivates the PI3K/Akt/GSK-3β signaling pathway in ESCC. After TE-8 and TE-12 cells were treated with UA (20 μM), DIM (50 μM), and a combination for 48 h. Akt/p-Akt and Gsk-3β/p-GSK 3β protein levels were examined by Western blot analysis. The quantification of protein bands was estimated by ImageJ software. GAPDH was used as the internal control. Data are expressed as the mean ± standard error of the mean. CONT, control; ESCC, esophageal squamous cell carcinoma; n.s., no significant. *, compared to the control; #, compare with UA plus DIM combination treatment. * or #, p < 0.05; ** or ##, p < 0.01.

• 

  Fig. 5 Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) actives the Hippo signaling pathway and down-regulates the target gene CTGF in ESCC. TE-8 and TE-12 cells were treated with UA (20 μM), DIM (50 μM), or combination treatment for 48 h. Western blot analysis was used to determine the Hippo signaling pathway: (A) Rassf1, Mst1, Mst2, Sav1, Mob-1, and p-Mob1, (B) YAP and p-YAP. (C) The Hippo signaling pathway CTGF mRNA level was detected by real-time PCR and (D) protein levels were examined by Western blot analysis. GAPDH was used as the internal control. Data are expressed as the mean ± standard error of the mean. CONT, control; ESCC, esophageal squamous cell carcinoma; n.s., no significant. *, compared to the control; #, compare with UA plus DIM combination treatment. * or #, p < 0.05; ** or ##, p < 0.01.

• 

  Fig. 6 Inhibition of the PI3K/Akt pathway stimulated by ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) combination treatment induces Hippo signaling pathway activation in ESCC. TE-8 and TE-12 cells were pre-treated with LY294002 (50 μM) or 3-MA (5 mM) for 2 h and further treated with UA (20 μM) plus DIM (50 μM) for 48 h. The expression of Hippo pathway-related proteins: (A) Rassf1, Mst1, Mst2, Sav1, Mob-1, p-Mob1, (B) YAP, and p-YAP and Hippo signaling pathway downstream proteins CTGF were examined by Western blotting. (C) Cytoplasm and nuclear proteins were separated to detect YAP distribution by Western blotting. GAPDH was used as the internal control and cytoplasm marker. Lamin B was used as a nuclear marker. (D) TE-8 and TE-12 cells were stained with anti-YAP antibody (green) and DAPI (blue) and visualized under fluorescence microscopy. Nuclei were stained by DAPI. The value of immunofluorescence was measured and calculated by ImageJ software. Data are expressed as the mean ± standard error of the mean. CONT, control; LY, LY294002; Mix, UA plus DIM; ESCC, esophageal squamous cell carcinoma; n.s., no significant. *, compared to the control; a, combined therapy (mix) compared with mix plus LY294002; #, mix compared with mix plus 3-MA. * or #, p < 0.05; **, ## or aa, p < 0.01.

• 

  Fig. 7 Knockdown of YAP accelerates ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) combination treatment induced down-regulation of the PI3K/Akt pathway by targeting PTEN protein expression in ESCC. Protein levels of Akt, p-Akt, PTEN, and p-PTEN were measured by Western blot analysis after YAP knockdown by siRNA 24 h following treatment with UA (20 μM) and DIM (50 μM) for 48 h. GAPDH was used as the internal control. Data are expressed as the mean ± standard error of the mean. CONT, control; KD, YAP siRNA knockdown; Mix, UA plus DIM; ESCC, esophageal squamous cell carcinoma; n.s., no significant. *, compared to the control; #, compare with mix plus YAP siRNA knockdown. * or #, p < 0.05; **p < 0.01; ***p < 0.001.

• 

  Fig. 8 Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) safely and effectively inhibits tumorigenesis through the PI3K/Akt signaling pathway and Hippo signaling pathway in a xenograft mouse model. TE-8 cells were subcutaneously injected into nude mice to create the xenograft mouse model. After tumors were established, mice were injected with UA, DIM, or combination treatment for 3 weeks. (A) Serum was extracted from mouse blood at 4°C. ALT, AST, BUN, and creatine were used as serum biochemical indices for drug safety evaluation. (B) Body weight and (C) tumor volume was measured every 3 days. (D) Tumor weights were measured after mice were sacrificed. (E) Tumor images were obtained after they were removed from mice. (F) H&E staining (left) and Ki67 staining (right) of tumor tissue (50 uM). Akt-related proteins (G) and Hippo pathway-related proteins (H) are analyzed by Western blotting. Data are expressed as the mean ± standard error of the mean. GAPDH was used as the internal control. CONT, control; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; n.s., no significant. *, compared to the control; #, compare with UA plus DIM combination treatment. * or #, p < 0.05; ** or ##, p < 0.01.

• 

  Fig. 9 Schematic diagram. Ursolic acid (UA) plus 3,3’-diindolylmethane (DIM) combination treatment can induce apoptosis by promoting cleaved-PARP and caspase-9, increasing the G1 phase by upregulating CDK4, CDK6, and Cyclin D1 protein expression, and inhibiting migration by regulating E-cadherin, MMP-9, and MMP-13 in esophageal squamous cell carcinoma (ESCC). UA plus DIM combination treatment lowered p-Akt and p-Gsk-3β expression in ESCC. UA plus DIM combination activated the Hippo signaling pathway leading to the inhibition of YAP de-phosphorylation and nuclear translocation and suppression of its downstream gene CTGF further restrained cell growth in ESCC. UA and DIM combination treatment induced the Hippo pathway activation by inhibiting the PI3K/Akt pathway in ESCC. UA plus DIM combination treatment can induce YAP inhibition by conversely inhibiting the PI3K/Akt pathway through up-regulated PTEN. UA plus DIM stimulated a feedback loop between the PI3K/Akt signaling pathway and Hippo signaling pathways in ESCC.

Reference

1. Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. 2020; Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 13:1010–1021. DOI: 10.1007/s12328-020-01237-x. PMID: 32965635.

2. Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, Gaduputi V. 2020; Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 11:55–64. DOI: 10.14740/wjon1254. PMID: 32284773. PMCID: PMC7141161.

3. Shin A, Won YJ, Jung HK, Kong HJ, Jung KW, Oh CM, Choe S, Lee J. 2018; Trends in incidence and survival of esophageal cancer in Korea: analysis of the Korea Central Cancer Registry Database. J Gastroenterol Hepatol. 33:1961–1968. DOI: 10.1111/jgh.14289. PMID: 29802647. PMCID: PMC6334276.

4. Sun D, Cao M, Li H, He S, Chen W. 2020; Cancer burden and trends in China: a review and comparison with Japan and South Korea. Chin J Cancer Res. 32:129–139. DOI: 10.21147/j.issn.1000-9604.2020.02.01. PMID: 32410791. PMCID: PMC7219092.

5. Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. 2021; Epidemiology, diagnosis, staging and multimodal therapy of esophageal and gastric tumors. Cancers (Basel). 13:582. DOI: 10.3390/cancers13030582. PMID: 33540736. PMCID: PMC7867245. PMID: f2dd64f9294344139bdb6b4ab170b9c1.

6. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. 2015; Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 21:7933–7943. DOI: 10.3748/wjg.v21.i26.7933. PMID: 26185366. PMCID: PMC4499337.

7. Luan S, Zeng X, Zhang C, Qiu J, Yang Y, Mao C, Xiao X, Zhou J, Zhang Y, Yuan Y. 2021; Advances in drug resistance of esophageal cancer: from the perspective of tumor microenvironment. Front Cell Dev Biol. 9:664816. DOI: 10.3389/fcell.2021.664816. PMID: 33816512. PMCID: PMC8017339. PMID: 35de3603f9c64442b10a87332ef70935.

8. Lindner K, Eichelmann AK, Matuszcak C, Hussey DJ, Haier J, Hummel R. 2018; Complex epigenetic regulation of chemotherapy resistance and biohlogy in esophageal squamous cell carcinoma via microRNAs. Int J Mol Sci. 19:499. Erratum in: Int J Mol Sci. 2019;20:921. DOI: 10.3390/ijms20040921. PMID: 30791591. PMCID: PMC6412518. PMID: dacafc1a8d7341df99f259a2fdc05199.

9. Krasna MJ. 2010; Multimodality therapy for esophageal cancer. Oncology (Williston Park). 24:1134–1138. PMID: 21141694.

10. Islami F, Ren JS, Taylor PR, Kamangar F. 2009; Pickled vegetables and the risk of oesophageal cancer: a meta-analysis. Br J Cancer. 101:1641–1647. DOI: 10.1038/sj.bjc.6605372. PMID: 19862003. PMCID: PMC2778505.

11. Higdon JV, Delage B, Williams DE, Dashwood RH. 2007; Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 55:224–236. DOI: 10.1016/j.phrs.2007.01.009. PMID: 17317210. PMCID: PMC2737735.

12. Khwaza V, Oyedeji OO, Aderibigbe BA. 2020; Ursolic acid-based derivatives as potential anti-cancer agents: an update. Int J Mol Sci. 21:5920. DOI: 10.3390/ijms21165920. PMID: 32824664. PMCID: PMC7460570. PMID: 60ea6e8af8944627b70f910451c0984a.

13. Alam M, Ali S, Ahmed S, Elasbali AM, Adnan M, Islam A, Hassan MI, Yadav DK. 2021; Therapeutic potential of ursolic acid in cancer and diabetic neuropathy diseases. Int J Mol Sci. 22:12162. DOI: 10.3390/ijms222212162. PMID: 34830043. PMCID: PMC8621142. PMID: e17bd67e0fb74c92a8e8c2850d80e840.

14. Kassi E, Papoutsi Z, Pratsinis H, Aligiannis N, Manoussakis M, Moutsatsou P. 2007; Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells. J Cancer Res Clin Oncol. 133:493–500. DOI: 10.1007/s00432-007-0193-1. PMID: 17516089.

15. Navin R, Kim SM. 2016; Therapeutic interventions using ursolic acid for cancer treatment. Med Chem (Los Angeles). 6:339–344. DOI: 10.4172/2161-0444.1000367.

16. Figueroa-Suárez MZ, González Christen J, Cardoso-Taketa AT, Gutiérrez Villafuerte MDC, Rodríguez-López V. 2019; Anti-inflammatory and antihistaminic activity of triterpenoids isolated from Bursera cuneata (Schldl.) Engl. J Ethnopharmacol. 238:111786. DOI: 10.1016/j.jep.2019.03.013. PMID: 30872171.

17. Habtemariam S. 2019; Antioxidant and anti-inflammatory mechanisms of neuroprotection by ursolic acid: addressing brain injury, cerebral ischemia, cognition deficit, anxiety, and depression. Oxid Med Cell Longev. 2019:8512048. DOI: 10.1155/2019/8512048. PMID: 31223427. PMCID: PMC6541953.

18. do Nascimento PG, Lemos TL, Bizerra AM, Arriaga ÂM, Ferreira DA, Santiago GM, Braz-Filho R, Costa JG. 2014; Antibacterial and antioxidant activities of ursolic acid and derivatives. Molecules. 19:1317–1327. DOI: 10.3390/molecules19011317. PMID: 24451251. PMCID: PMC6271190. PMID: 25fcb9a47785495fb68e2ddcc5134986.

19. Hassan HM, Jiang ZH, Asmussen C, McDonald E, Qin W. 2014; Antibacterial activity of northern Ontario medicinal plant extracts. Can J Plant Sci. 94:417–424. DOI: 10.4141/cjps2013-258.

20. Lee NR, Meng RY, Rah SY, Jin H, Ray N, Kim SH, Park BH, Kim SM. 2020; Reactive oxygen species-mediated autophagy by ursolic acid inhibits growth and metastasis of esophageal cancer cells. Int J Mol Sci. 21:9409. DOI: 10.3390/ijms21249409. PMID: 33321911. PMCID: PMC7764507. PMID: 32da4af9afe64e46a080552397a0fd6a.

21. Yang K, Chen Y, Zhou J, Ma L, Shan Y, Cheng X, Wang Y, Zhang Z, Ji X, Chen L, Dai H, Zhu B, Li C, Tao Z, Hu X, Yin W. 2019; Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations. Br J Pharmacol. 176:4609–4624. DOI: 10.1111/bph.14793. PMID: 31322286. PMCID: PMC6965687.

22. Huang CY, Lin CY, Tsai CW, Yin MC. 2011; Inhibition of cell proliferation, invasion and migration by ursolic acid in human lung cancer cell lines. Toxicol In Vitro. 25:1274–1280. DOI: 10.1016/j.tiv.2011.04.014. PMID: 21539908.

23. Hsu YL, Kuo PL, Lin CC. 2004; Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci. 75:2303–2316. DOI: 10.1016/j.lfs.2004.04.027. PMID: 15350828.

24. Kim SH, Jin H, Meng RY, Kim DY, Liu YC, Chai OH, Park BH, Kim SM. 2019; Activating Hippo pathway via Rassf1 by ursolic acid suppresses the tumorigenesis of gastric cancer. Int J Mol Sci. 20:4709. DOI: 10.3390/ijms20194709. PMID: 31547587. PMCID: PMC6801984. PMID: 098852b82a354918a8075acbca83ab19.

25. Kim ES, Moon A. 2015; Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells. Oncol Lett. 9:897–902. DOI: 10.3892/ol.2014.2735. PMID: 25621065.

26. Liu T, Ma H, Shi W, Duan J, Wang Y, Zhang C, Li C, Lin J, Li S, Lv J, Lin L. 2017; Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma. Int J Oncol. 51:555–562. DOI: 10.3892/ijo.2017.4035. PMID: 28714512.

27. Zhou W, Lin L, Cheng Y, Liu Y. 2017; Ursolic acid improves liver transplantation and inhibits apoptosis in miniature pigs using donation after cardiac death. Cell Physiol Biochem. 43:331–338. DOI: 10.1159/000480413. PMID: 28854432. PMID: 3807e3e23c2b462a9ee8951cbd5259df.

28. Shanmugam MK, Rajendran P, Li F, Nema T, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Ho PC, Hui KM, Sethi G. 2011; Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med (Berl). 89:713–727. DOI: 10.1007/s00109-011-0746-2. PMID: 21465181.

29. Ye Y, Fang Y, Xu W, Wang Q, Zhou J, Lu R. 2016; 3,3'-Diindolylmethane induces anti-human gastric cancer cells by the miR-30e-ATG5 modulating autophagy. Biochem Pharmacol. 115:77–84. DOI: 10.1016/j.bcp.2016.06.018. PMID: 27372603.

30. Li XJ, Park ES, Park MH, Kim SM. 2013; 3,3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway. Oncol Rep. 30:2419–2426. DOI: 10.3892/or.2013.2717. PMID: 24008339.

31. Jin H, Park MH, Kim SM. 2015; 3,3'-Diindolylmethane potentiates paclitaxel-induced antitumor effects on gastric cancer cells through the Akt/FOXM1 signaling cascade. Oncol Rep. 33:2031–2036. DOI: 10.3892/or.2015.3758. PMID: 25633416.

32. Zhu P, Yu H, Zhou K, Bai Y, Qi R, Zhang S. 2020; 3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE₂ pathway. J Exp Clin Cancer Res. 39:113. DOI: 10.1186/s13046-020-01618-7. PMID: 32546278. PMCID: PMC7298755. PMID: 55aa1451e2f54bc69fa9687a08cc3b69.

33. Kim SJ, Lee JS, Kim SM. 2012; 3,3'-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep. 27:1669–1673. DOI: 10.3892/or.2012.1662. PMID: 22293900.

34. Li XJ, Leem SH, Park MH, Kim SM. 2013; Regulation of YAP through an Akt-dependent process by 3, 3'-diindolylmethane in human colon cancer cells. Int J Oncol. 43:1992–1998. DOI: 10.3892/ijo.2013.2121. PMID: 24100865.

35. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR, Sarkar FH. 2008; Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res. 68:1927–1934. DOI: 10.1158/0008-5472.CAN-07-3241. PMID: 18339874. PMCID: PMC3757473.

36. Rahman KW, Sarkar FH. 2005; Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res. 65:364–371. DOI: 10.1158/0008-5472.364.65.1. PMID: 15665315.

37. Han Y. 2019; Analysis of the role of the Hippo pathway in cancer. J Transl Med. 17:116. DOI: 10.1186/s12967-019-1869-4. PMID: 30961610. PMCID: PMC6454697. PMID: 8a32b04a45634498900b8618a3e93fb5.

38. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. 2021; Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 6:425. DOI: 10.1038/s41392-021-00828-5. PMID: 34916492. PMCID: PMC8677728. PMID: 37774d4ae5334c1a9a597cb056b37cdb.

39. Luo Q, Du R, Liu W, Huang G, Dong Z, Li X. 2022; PI3K/Akt/mTOR signaling pathway: role in esophageal squamous cell carcinoma, regulatory mechanisms and opportunities for targeted therapy. Front Oncol. 12:852383. DOI: 10.3389/fonc.2022.852383. PMID: 35392233. PMCID: PMC8980269. PMID: 3457337e85a54ddeb424fb2bdb7d8419.

40. Javadinia SA, Shahidsales S, Fanipakdel A, Mostafapour A, Joudi-Mashhad M, Ferns GA, Avan A. 2018; The esophageal cancer and the PI3K/AKT/mTOR signaling regulatory microRNAs: a novel marker for prognosis, and a possible target for immunotherapy. Curr Pharm Des. 24:4646–4651. DOI: 10.2174/1381612825666190110143258. PMID: 30636576.

41. Zhu C, Li L, Zhao B. 2015; The regulation and function of YAP transcription co-activator. Acta Biochim Biophys Sin (Shanghai). 47:16–28. DOI: 10.1093/abbs/gmu110. PMID: 25487920.

42. Misra JR, Irvine KD. 2018; The Hippo signaling network and its biological functions. Annu Rev Genet. 52:65–87. DOI: 10.1146/annurev-genet-120417-031621. PMID: 30183404. PMCID: PMC6322405.

43. Yu FX, Zhao B, Guan KL. 2015; Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163:811–828. DOI: 10.1016/j.cell.2015.10.044. PMID: 26544935. PMCID: PMC4638384.

44. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL. 2012; YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol. 14:1322–1329. DOI: 10.1038/ncb2615. PMID: 23143395. PMCID: PMC4019071.

45. Qian X, He L, Hao M, Li Y, Li X, Liu Y, Jiang H, Xu L, Li C, Wu W, Du L, Yin X, Lu Q. 2021; YAP mediates the interaction between the Hippo and PI3K/Akt pathways in mesangial cell proliferation in diabetic nephropathy. Acta Diabetol. 58:47–62. DOI: 10.1007/s00592-020-01582-w. PMID: 32816106.

46. Ye X, Deng Y, Lai ZC. 2012; Akt is negatively regulated by Hippo signaling for growth inhibition in Drosophila. Dev Biol. 369:115–123. DOI: 10.1016/j.ydbio.2012.06.014. PMID: 22732571.

47. Borreguero-Muñoz N, Fletcher GC, Aguilar-Aragon M, Elbediwy A, Vincent-Mistiaen ZI, Thompson BJ. 2019; The Hippo pathway integrates PI3K-Akt signals with mechanical and polarity cues to control tissue growth. PLoS Biol. 17:e3000509. DOI: 10.1371/journal.pbio.3000509. PMID: 31613895. PMCID: PMC6814241. PMID: 49700236fbce48088ee3945b33c7f241.

48. Hu LL, Su T, Luo RC, Zheng YH, Huang J, Zhong ZS, Nie J, Zheng LP. 2019; Hippo pathway functions as a downstream effector of AKT signaling to regulate the activation of primordial follicles in mice. J Cell Physiol. 234:1578–1587. DOI: 10.1002/jcp.27024. PMID: 30078193.

49. Lin Z, Zhou P, von Gise A, Gu F, Ma Q, Chen J, Guo H, van Gorp PR, Wang DZ, Pu WT. 2015; Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ Res. 116:35–45. DOI: 10.1161/CIRCRESAHA.115.304457. PMID: 25249570. PMCID: PMC4282610.

50. Xu W, Yang Z, Xie C, Zhu Y, Shu X, Zhang Z, Li N, Chai N, Zhang S, Wu K, Nie Y, Lu N. 2018; PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis. J Exp Clin Cancer Res. 37:198. DOI: 10.1186/s13046-018-0795-2. PMID: 30134988. PMCID: PMC6104022. PMID: fa829ec5bd6b4945a08ad9b0211c1d69.

51. Worby CA, Dixon JE. 2014; PTEN. Annu Rev Biochem. 83:641–669. DOI: 10.1146/annurev-biochem-082411-113907. PMID: 24905788.

52. Zou R, Xu Y, Feng Y, Shen M, Yuan F, Yuan Y. 2020; YAP nuclear-cytoplasmic translocation is regulated by mechanical signaling, protein modification, and metabolism. Cell Biol Int. 44:1416–1425. DOI: 10.1002/cbin.11345. PMID: 32190949.

53. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. 2019; Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 16:1–24. Erratum in: Esophagus. 2022;19:726. DOI: 10.1007/s10388-018-0641-9. PMID: 30171413. PMCID: PMC6510883.

54. Meng RY, Jin H, Nguyen TV, Chai OH, Park BH, Kim SM. 2021; Ursolic acid accelerates paclitaxel-induced cell death in esophageal cancer cells by suppressing Akt/FOXM1 signaling cascade. Int J Mol Sci. 22:11486. DOI: 10.3390/ijms222111486. PMID: 34768915. PMCID: PMC8584129. PMID: d28bd70cecc64f66bf6cb2ef10fc4235.

55. Biersack B. 2020; 3,3'-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs. Cancer Drug Resist. 3:867–878. DOI: 10.20517/cdr.2020.53. PMID: 35582221. PMCID: PMC8992569.

56. Lin W, Ye H. 2020; Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway. J BUON. 25:750–756. PMID: 32521863.

57. Meng Y, Lin ZM, Ge N, Zhang DL, Huang J, Kong F. 2015; Ursolic acid induces apoptosis of prostate cancer cells via the PI3K/Akt/mTOR pathway. Am J Chin Med. 43:1471–1486. DOI: 10.1142/S0192415X15500834. PMID: 26503559.

58. Wong RS. 2011; Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 30:87. DOI: 10.1186/1756-9966-30-87. PMID: 21943236. PMCID: PMC3197541. PMID: 14037097dac24b9dae7629da9c125275.

59. Tahtamouni L, Ahram M, Koblinski J, Rolfo C. 2019; Molecular regulation of cancer cell migration, invasion, and metastasis. Anal Cell Pathol (Amst). 2019:1356508. DOI: 10.1155/2019/1356508. PMID: 31218208. PMCID: PMC6536998. PMID: a0407114b4874fdb92140eab9fe3e998.

60. Shin JY, Kim JO, Lee SK, Chae HS, Kang JH. 2010; LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer. 10:425. DOI: 10.1186/1471-2407-10-425. PMID: 20704765. PMCID: PMC3087326. PMID: e37d2abf32d94d3ca2610f5c88c54213.

61. Datta S, Cano M, Satyanarayana G, Liu T, Wang L, Wang J, Cheng J, Itoh K, Sharma A, Bhutto I, Kannan R, Qian J, Sinha D, Handa JT. 2023; Mitophagy initiates retrograde mitochondrial-nuclear signaling to guide retinal pigment cell heterogeneity. Autophagy. 19:966–983. DOI: 10.1080/15548627.2022.2109286. PMID: 35921555. PMCID: PMC9980637.

62. Domoto T, Pyko IV, Furuta T, Miyashita K, Uehara M, Shimasaki T, Nakada M, Minamoto T. 2016; Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy. Cancer Sci. 107:1363–1372. DOI: 10.1111/cas.13028. PMID: 27486911. PMCID: PMC5084660.

63. Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L, Ratti S, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D, McCubrey JA. 2020; Targeting GSK3 and associated signaling pathways involved in cancer. Cells. 9:1110. DOI: 10.3390/cells9051110. PMID: 32365809. PMCID: PMC7290852. PMID: 4013e82b8ba443de968a8ae058a04c3d.

64. Fu Y, Sun S, Sun H, Peng J, Ma X, Bao L, Ji R, Luo C, Gao C, Zhang X, Jin Y. 2019; Scutellarin exerts protective effects against atherosclerosis in rats by regulating the Hippo-FOXO3A and PI3K/AKT signaling pathways. J Cell Physiol. 234:18131–18145. DOI: 10.1002/jcp.28446. PMID: 30891776.